A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

• ClinicalTrials.gov Identifier: NCT05163288
• Recruitment Status: Active, not recruiting
• First Posted: December 20, 2021
• Last Update Posted: September 13, 2023
• Sponsor: IntraBio Inc
• Information provided by (Responsible Party): IntraBio Inc

Study Description

Brief Summary:

A pivotal, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Niemann Pick disease type C (NPC). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leucine (IB1001) compared to standard of care.

Condition or disease	Intervention/treatment	Phase
Niemann-Pick Disease, Type C	Drug: N-Acetyl-L-Leucine; Other: Placebo	Phase 3

Detailed Description:

This is a multinational, randomized, placebo-controlled, double-blinded, cross-over Phase III study that will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) versus Placebo for the treatment of Niemann-Pick type C disease (NPC).

Patients will be assessed during three study periods: a baseline period (approximately 2-weeks), after which they will be randomized (1:1) to receive treatment with IB1001 or Placebo for approximately 12-weeks during the first intervention period ("Period I"). Following Period I, patients will crossover to receive the opposite treatment (IB1001 or Placebo) for approximately 12-weeks during a second intervention period ("Period II).

Patients will be assessed twice during each study period. Patients who have participated in the study may be offered the opportunity to roll over into an Extension Phase, which is planned to allow patients to have further access to IB1001.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 53 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: Randomized, placebo-controlled, double-blind, crossover, multi-center, study with 1:1 randomization of IB1001 plus SOC for 12-weeks versus placebo plus SOC for 12-weeks, followed by open-label extension study.
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C (NPC): A Phase III, Randomized, Placebo-controlled, Double-blind, Crossover Study
• Actual Study Start Date: June 30, 2022
• Actual Primary Completion Date: June 12, 2023
• Estimated Study Completion Date: November 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: N-acetyl-L-leucine (IB1001); Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.	Drug: N-Acetyl-L-Leucine; N-Acetyl-L-Leucine is a modified amino-acid ester that is orally administered (granules for suspension in a sachet); Other Name: IB1001
Placebo Comparator: Placebo comparator; Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.	Other: Placebo; Matching Placebo Sachet

Outcome Measures

Primary Outcome Measures :

1. Scale for the Assessment and Rating of Ataxia (all jurisdictions except US) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
2. Modified Scale for the Assessment and Rating of Ataxia (US only) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]

Secondary Outcome Measures :

1. Spinocerebellar Ataxia Functional Index (SCAFI) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
2. Modified Disability Rating Scale [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
3. Physician's / Caregiver's / Patient's Clinical Global Impressions (CGI) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
4. EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
5. Scale for the Assessment and Rating of Ataxia (US only) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]

Other Outcome Measures:

1. Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
2. 5-Domain Niemann-Pick disease type C Clinical Severity Scale (NPC-CSS) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
3. Investigator's / Caregiver's / Patient's Clinical Global Impressions (CGI) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]
4. Modified Scale for the Assessment and Rating of Ataxia (all jurisdictions except US) [ Time Frame: End of Period I (week 12) vs. End of Period 2 (week 24) ]

Eligibility Criteria

• Ages Eligible for Study: 4 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Written informed consent signed by the patient and/or their legal representative/ parent/ impartial witness
2. Male or female aged ≥4 years with a confirmed genetic diagnosis of NPC at the time of signing informed consent.

3. Females of childbearing potential, defined as a premenopausal female capable of becoming pregnant, will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first dose and confirm to continue through 28 days after the last dose) or using one of the following highly effective contraceptives (i.e. results in <1% failure rate when used consistently and correctly) 14 days prior to the first dose continuing through 28 days after the last dose:

   1. intrauterine device (IUD);
   2. surgical sterilization of the partner (vasectomy for 6 months minimum);
   3. combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal);
   4. progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable);
   5. intrauterine hormone releasing system (IUS);
   6. bilateral tubal occlusion.

4. Females of non-childbearing potential who have undergone one of the following sterilization procedures at least 6 months prior to the first dose:

   1. hysteroscopic sterilization;
   2. bilateral tubal ligation or bilateral salpingectomy;
   3. hysterectomy;
   4. bilateral oophorectomy; OR be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status. FSH analysis for postmenopausal women will be done at screening. FSH levels should be in the postmenopausal range as determined by the central laboratory.

5. Non-vasectomized male patient agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication and the female partner agrees to comply with inclusion criteria 3 or 4.

   For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male.

6. If male, patient agrees not to donate sperm from the first dose until 90 days after their last dose.

7. Patients must fall within:

   a) A SARA score of 7 ≤ X ≤ 34 points (out of 40) AND b) Either: i. Within the 2-7 range (0-8 range) of the Gait subtest of the SARA scale OR ii. Be able to perform the 9-Hole Peg Test with Dominant Hand (9HPT-D) (SCAFI subtest) in 20 ≤ X ≤150 seconds.

8. Weight ≥15 kg at screening.

9. Patients are willing to disclose their existing medications/therapies for (the symptoms) of NPC including those on the prohibited medication list. Non-prohibited medications/therapies (authorized medicines for NPC [e.g. miglustat], speech therapy, and physiotherapy) are permitted provided:

   1. The Investigator does not believe the medication/therapy will interfere with the study protocol/results
   2. Patients have been on a stable dose/duration and type of therapy for at least 42 days before Visit 1 (Baseline 1)
   3. Patients are willing to maintain a stable dose/do not change their therapy throughout the duration of the study.
10. An understanding of the implications of study participation, provided in the written patient information and informed consent by patients or their legal representative/parent, and demonstrates a willingness to comply with instructions and attend required study visits (for children this criterion will also be assessed in parents or appointed guardians).

Exclusion Criteria:

1. Patients who are unable to consistently Patients who have any known hypersensitivity or history of hypersensitivity to:

   1. Acetyl-Leucine (DL-, L-, D-) or derivatives.
   2. Excipients the IB1001 sachet (namely isomalt, hypromellose, and strawberry flavour).
   3. Excipients the placebo sachet (namely isomalt, hypromellose, strawberry flavour, citric acid, microcrystalline cellulose, lactose, denatonium benzoate).
2. Simultaneous participation in another clinical study or participation in any clinical study involving administration of an investigational medicinal product (IMP; 'study drug') for at least 42 days prior to Visit 1. At the discretion of the investigator, Medical Monitor, and Sponsor, the washout period for specific IMPs may be longer based on the pharmacological activity and pharmacokinetics of the drug.
3. Patients with a physical, cognitive, or psychiatric condition which, at the investigator's discretion and in consultation with the Medical Monitor and Sponsor (as applicable), may put the patient at risk, may confound the study results, or may interfere with the patient's participation in the clinical study, i.e. reliably perform study assessments.
4. Known or persistent use, misuse, or dependency of medication, drugs, or alcohol.
5. Current or planned pregnancy or women who are breastfeeding.
6. Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments.
7. Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments.

8. Patients unwilling and/or not able to undergo a 42 day period from any of the following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited medication through Visit 6.

   1. N-Acetyl-DL-Leucine (e.g. Tanganil®);
   2. N-Acetyl-L-Leucine (prohibited if not provided as IMP in the IB1001-301 trial);
   3. Sulfasalazine;

   4. Rosuvastatin.

      -

Contacts and Locations

Locations

United States, Minnesota

Mayo Clinic

Rochester, Minnesota, United States, 55905

Australia, Victoria

The Royal Melbourne Hospital

Parkville, Victoria, Australia, 3050

Czechia

First Faculty of Medicine, Charles University Hospital Prague

Praha, Czechia, 128 08

Germany

University of Giessen

Gießen, Germany, 35389

University of Hamburg

Hamburg, Germany, 20246

SphinCS - Institute of Clinical Science in Lysosomal Storage Disorders

Hochheim, Germany, 65239

Ludwig Maximilian University of Munich

München, Germany, 80539

University Hospital Münster

Münster, Germany, 48149

Netherlands

Amsterdam UMC

Amsterdam, Netherlands, 1105

Slovakia

Comenius University in Bratislva

Bratislava, Slovakia, 833 40

Switzerland

University Hospital Bern Inselspital

Bern, Switzerland, 3010

United Kingdom

Great Ormond Street Hospital

London, United Kingdom, WC1N 3JH

Royal Free London NHS Foundation Trust

London, United Kingdom

Royal Manchester Children's Hospital

Manchester, United Kingdom, M13 9WL

Sponsors and Collaborators

IntraBio Inc

More Information

Publications of Results:

Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, Hassan A, Hennig A, Jones SA, Kolnikova M, Martakis K, Raethjen J, Ramaswami U, Sharma R, Schneider SA. Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C. J Neurol. 2022 Mar;269(3):1651-1662. doi: 10.1007/s00415-021-10717-0. Epub 2021 Aug 13.

Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, Fineran P, Morten KJ, Poulton J, Boland B, Spencer J, Strupp M, Platt FM. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 2020 Dec 20;3(1):fcaa148. doi: 10.1093/braincomms/fcaa148. eCollection 2021.

Cortina-Borja M, Te Vruchte D, Mengel E, Amraoui Y, Imrie J, Jones SA, I Dali C, Fineran P, Kirkegaard T, Runz H, Lachmann R, Bremova-Ertl T, Strupp M, Platt FM. Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials. Orphanet J Rare Dis. 2018 Aug 16;13(1):143. doi: 10.1186/s13023-018-0880-9.

• Responsible Party: IntraBio Inc
• ClinicalTrials.gov Identifier: NCT05163288
• Other Study ID Numbers: IB1001-301
• First Posted: December 20, 2021
• Last Update Posted: September 13, 2023
• Last Verified: September 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: The results of the study will be published within a reasonable timeframe of completion. Pseudonymised individual patient data may be available in these findings.

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Pick Disease of the Brain; Aphasia, Primary Progressive; Frontotemporal Dementia; Niemann-Pick Diseases; Niemann-Pick Disease, Type A; Niemann-Pick Disease, Type C; Frontotemporal Lobar Degeneration; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders; Aphasia; Speech Disorders; Language Disorders; Communication Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; TDP-43 Proteinopathies; Neurodegenerative Diseases; Proteostasis Deficiencies; Metabolic Diseases; Sphingolipidoses; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Lymphatic Diseases